Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow Inc. has demonstrated strong growth potential, with VEVYE revenue increasing 22% quarter-over-quarter to $22.6 million in the third quarter of 2025, alongside a notable 10.5% market share in the national dry eye disease sector. The company’s VEVYE Access for All program is successfully enhancing patient accessibility and driving demand, with an anticipated strengthening of VEVYE's positioning due to upcoming real-world evidence showcasing significant clinical improvements. With projections to achieve a quarterly revenue of $250 million by the fourth quarter of 2027, supported by new product launches and improved insurance coverage, Harrow Inc.'s stock outlook remains positive as it capitalizes on growth opportunities in the ophthalmic market.

Bears say

Harrow Inc. has revised its FY26 revenue expectations down to $352 million from $459 million, primarily due to a worse-than-anticipated sequential decline in first-quarter revenue, contributing to a year-to-date equity weakness of -30%. Additionally, the company’s EBITDA projection of $76 million falls below the previously established guidance range of $80 million to $100 million, reflecting conservative assumptions regarding first-half revenue performance. Concerns over clinical development outcomes, regulatory approvals for pipeline products, and potential dilution risks further compound the negative outlook, suggesting that if product adoption fails to materialize as expected, the company's valuation could be significantly impacted.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.